Wall Street analysts almost never announce that they were wrong. They reprice instead.
That habit is worth keeping in mind whenever a bank moves a stock two full rating notches before the opening bell, because the useful information is usually buried underneath the rating, not in it.
Consider the corner of the market that has spent three years absorbing punishment for a sin it stopped committing a while ago.
Life sciences tools companies sell the instruments, reagents, and outsourced lab services that drug developers can’t operate without. They boomed through the Covid pandemic, then fell hard when biotech funding dried up, academic budgets froze, and Chinese demand went quiet.
Earnings, though, never actually broke. They just stopped getting paid for. Revenue continued compounding, margins kept widening, and the multiple kept shrinking anyway.
That gap between profits and price is the setup behind one of the more aggressive analyst calls of the week, and behind a price target that landed a long way from where the rest of the Street is standing.
Thermo Fisher Scientific (TMO), the largest company in the group, was upgraded to Buy from Neutral at UBS on Sept. 9, and the firm boosted its price target on the shares to $730 from $540, according to 24/7 Wall St.
That is roughly $190 added to a number the firm had been sitting on. Banks do not usually move that far in one motion, and the reason this one did has almost nothing to do with the last earnings report.
Why life sciences tools stocks stopped working
Thermo Fisher’s earnings per share has grown about 7% a year over the past three years while the share price has gone essentially nowhere, according to Simply Wall St. That is a de-rating, not a deterioration.
The cause, when I went back through the demand picture, was that every customer group went cold at once.
Pharma and biotech, which account for roughly 60% of Thermo Fisher’s revenue, cut discretionary spending. Academic and government labs sat on frozen budgets. China, once the group’s growth engine, contracted for several straight quarters.
Related: UBS revamps S&P 500 target for rest of 2026
Instrument purchases are the first line item a lab defers and the last one it restores. That turned a health care name into something that trades like an early-cycle industrial, which is exactly what happened to the multiple.
The wider market spent the same stretch paying up for anything with an artificial intelligence (AI) attachment, a rotation that left slower compounders stranded.
What UBS actually changed on Thermo Fisher
The upgrade did not come out of the second-quarter print. It came out of the 2027 model.
Thermo Fisher is positioned for “a durable return to 5%-6%-plus organic growth in 2027,” the firm told investors in a research note, reported TheFly.
More Wall Street:
- SpaceX investors get bold Wall Street price target for 2027 year-end
- Anthropic sends clear message to Wall Street ahead of IPO
- Bank of America’s unique take on Apple stock as Ternus takes reins
Alongside that growth call, UBS projects operating margin expansion of at least 50 to 70 basis points and double-digit earnings per share growth, according to Investing.com.
The drivers it lists are better pharma and biotech funding, reshoring investment, sustained bioprocessing demand, AI-driven gains in research and development returns, market share gains, and stabilization in China and in academic and government spending.
Here is where the number sits relative to everyone else’s:
- UBS raised its target to $730 from $540 while moving to Buy from Neutral, according to 24/7 Wall St.
- CLSA analyst Michael Luo started coverage at Outperform with a $748 target on Sept. 3, above the UBS number, according to StockAnalysis.
- The average 12-month target across the 29 analysts covering the stock is about $638, according to StockAnalysis.
When I lined the $730 up against that $638 average, the spread was the tell. UBS is not nudging a model. It is sitting roughly 14% above where the rest of the Street has settled, and it got there in one jump rather than through the usual quarterly drift.
The analyst handoff hiding inside the upgrade
Most of the coverage treated this as a bank changing its mind. That is not quite what happened.
The rating change arrived as UBS assumed coverage of the stock with a new analyst, according to Investing.com.
That distinction matters more than it sounds. A coverage transfer means the person who defended the Neutral rating is no longer the person writing the note. Incoming analysts routinely reset a predecessor’s stance in their first publication, and those resets tend to be large precisely because they are catching up all at once, instead of adjusting a quarter at a time.
My read is that UBS is not calling a bottom in laboratory demand. It is calling the end of a de-rating, and it is doing it through a fresh set of eyes. Anyone treating this as a firm publicly reversing itself is reading the wrong signal.
What a 2027 growth reset would mean for the stock
The recovery evidence is already on the tape, which is part of why the target moved so far.
Second-quarter revenue grew 10% to $11.99 billion, including 5% organic growth. Adjusted operating margin expanded 90 basis points to 22.8%, and adjusted earnings per share rose 13% to $6.03, according to the company’s second-quarter results. Chairman and CEO Marc Casper cited “outstanding performance in the second quarter” in that release.
Full-year guidance went to $47.4 billion to $48.1 billion in revenue, with adjusted earnings per share of $24.93 to $25.33.
The detail that should interest anyone modeling 2027 is geographic. China grew in the low single digits for the first time in several quarters, and academic and government spending returned to growth, reported GenomeWeb. Management stopped short of calling the academic recovery durable.
Two things have to hold for the UBS math to work:
- Pharma and biotech budgets need to keep loosening into next year.
- That academic thaw must prove structural rather than seasonal.
For a reader with a retirement account rather than a trading screen, the practical version is simpler. This is the kind of position that quietly underperformed for three years while its profits did not, and a growth reset in 2027 would close that gap without management doing anything heroic.
Shares traded near $606 on Sept. 9, putting the UBS target about 20% above the market. None of the 2027 thesis becomes testable until well into next year, which makes the next four quarters a referendum on whether the funding thaw is real.
That, not the target, is the number worth watching.
Related: UBS sends investors strong message about the economy
